Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach (TAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02363517
Recruitment Status : Unknown
Verified April 2018 by Macfarlane Burnet Institute for Medical Research and Public Health Ltd.
Recruitment status was:  Recruiting
First Posted : February 16, 2015
Last Update Posted : April 10, 2018
Sponsor:
Collaborator:
St Vincent's Hospital Melbourne
Information provided by (Responsible Party):
Macfarlane Burnet Institute for Medical Research and Public Health Ltd

Brief Summary:
This study will investigate the feasibility of treating people who inject drugs (PWID) with hepatitis C virus (HCV) in community-based settings with a 12-week course of oral therapy combination of sofosbuvir plus ledipasvir. It will also measure the effectiveness of using a social network-based approach to reduce HCV incidence among PWID.

Condition or disease Intervention/treatment Phase
Hepatitis C Drug Abuse, Intravenous Drug: Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) Phase 3

Detailed Description:

This study will investigate the feasibility of treating people who inject drugs (PWID) with hepatitis C virus (HCV) in community-based settings with a 12-week course of oral therapy combination of sofosbuvir plus ledipasvir (SOF + LDP). It will also measure the effectiveness of using a social network-based approach ("bring your friends") to reduce HCV incidence among PWID. Participants will initially be sourced from the Burnet Institute's existing SuperMIX cohort (N= 757). This cohort comprises PWID followed for between two and six years (median=1057 days), of whom 299 have chronic HCV infection. The HCV genotype distribution in the SuperMIX cohort is: HCV-1 (55%); HCV-3 (40%) and HCV-6 (<5%).

Participants will be randomly allocated to three groups:

Group 1: Primary (n=40) and secondary (n=100) participants will receive supportive care only.

Group 2: Primary participants (n=40) will be treated with SOF + LDP for 12 weeks. Secondary participants (n=100) will receive supportive care only.

Group 3: Primary (n=40) and secondary participants with chronic HCV infection (n=50%*100) will be treated with SOF + LDP for 12 weeks. Participants in Group C who have evidence of HCV re-infection will be offered re-treatment with SOF + LDP for 12 weeks.

Treatment participants will have a clinical review, questionnaire and blood sample collected at baseline, weeks 4, 8 and 12 (end-of-treatment), and at weeks 12 (SVR12), 24 (SVR24), 36, 48, 60 and 72 post-treatment. Non-treatment participants will have a clinical review, questionnaire and blood sample collected at baseline and weeks 12, 24, 36, 48, 60, 72 and 84.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 420 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Treatment And Prevention (TAP) Study: Treating People Who Inject Drugs (PWID) in Community-based Settings Using a Social Network Approach
Actual Study Start Date : February 2015
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Sofosbuvir

Arm Intervention/treatment
No Intervention: Group A

Primary (n=40) and secondary (n=100) participants will receive supportive care only (includes a clinical review, questionnaire and blood sample collected at baseline and weeks 12, 24, 36, 48, 60, 72 and 84).

Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period.

Active Comparator: Group B

Primary participants (n=40) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Secondary participants (n=100) will receive supportive care only.

Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period.

Drug: Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)
SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
Other Name: Standard of care

Active Comparator: Group C
Primary (n=40) and secondary participants with chronic HCV infection (approx. n=50%*100) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Participants in Group C who have evidence of HCV re-infection will be offered re-treatment with SOF + LDP for 12 weeks.
Drug: Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)
SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
Other Name: Standard of care




Primary Outcome Measures :
  1. The efficacy of treating PWID with HCV using 12 weeks of oral therapy via a community-based, nurse-led treatment model, as measured by SVR rates [ Time Frame: Change in sustained viral response rates at weeks 12 and 24 post-treatment. Participant retention rate at weeks 4, 8 and 12 (end of treatment). ]
  2. The effectiveness of treating PWID on rates of HCV primary infection and reinfection among their social networks, as measured by HCV incidence rates among primary and secondary participants [ Time Frame: Changes in rates of HCV primary infection and reinfection at weeks 12, 24, 36, 48, 60, 72 and 84 ]
    Hypothesis: Offering HCV treatment to PWID will lead to a lower incidence of transmission of HCV from primary participants to their injecting partners, compared to not treating any PWID.

  3. The effectiveness of treating PWID using a "bring your friends" strategy on rates of HCV primary infection and reinfection, as measured by HCV incidence rates among participants [ Time Frame: Changes in rates of HCV primary infection and reinfection at weeks 12, 24, 36, 48, 60, 72 and 84 ]
  4. The feasibility of treating PWID with HCV using 12 weeks of oral therapy via a community-based, nurse-led treatment model, as measured by SVR rates and participant retention [ Time Frame: Change in participant retention rates at weeks 4, 8 and 12 (end of treatment) ]

Secondary Outcome Measures :
  1. Changes in levels of injecting risk behaviours among participants following HCV treatment, as measured by self-reported frequency of risky injecting behaviours among participants [ Time Frame: Weeks 12, 24, 36, 48, 60, 72 and 84 ]
  2. Changes to Quality of Life (QoL) among treated participants versus non-treated participants, as measured by self-reported responses to validated QoL scales [ Time Frame: Weeks 12, 24, 36, 48, 60, 72 and 84 ]
  3. The prevalence of HCV resistance associated variants among treated participants who do not achieve SVR12 [ Time Frame: At 12 weeks post-treatment (SVR12) and weeks 24 (SVR24), 36, 48, 60 and 72 post-treatment ]
  4. Changes in the level of transient liver elastography readings (measured using Fibroscan®) among treated participants versus non-treated participants [ Time Frame: Up to 84 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

SECONDARY PARTICIPANTS INCLUSION AND EXCLUSION CRITERIA

Study INCLUSION criteria for primary participants are as follows:

  • Current PWID (i.e., injected any drug at least once during the previous six months);
  • Evidence of chronic HCV infection (detectable plasma HCV RNA viral load above 1000 IU/ml on two occasions ≥ 6 months apart)
  • Willing and able to provide written informed consent.

Subjects must have the following laboratory parameters at screening:

  • ALT <10 times the upper limit of normal (ULN)
  • AST <10 times ULN
  • Haemoglobin ≥12g/dL for males, ≥11g/dL for female subjects
  • INR ≤1.5 times ULN unless is stable on an anticoagulant regimen affecting INR
  • Albumin ≥3g/dL
  • Direct bilirubin ≤1.5 times ULN
  • Creatinine clearance (CLcr) ≥60mL/min, as calculated by the Cockcroft-Gault Equation.

EXCLUSION criteria for all primary participants are as follows:

  • Testing positive for HIV
  • History of, or current, decompensated liver disease
  • Testing positive for HBsAg
  • HCC
  • Women who are pregnant or breastfeeding, or men with female partners who are pregnant at screening or baseline, or who were pregnant in the six months prior to screening
  • Already enrolled in the TAP Study as a secondary participant (see below)
  • Evidence of any condition, therapy, laboratory abnormality or other circumstance (current or prior) that may confound the study's results, or interfere with participation for the full duration of the study, such that it is not in the best interest of the participant;
  • Use of concomitant medications.

Additional EXCLUSION criteria for primary participants with HCV genotypes 2-6:

  • Increased baseline risk for anaemia (e.g., a history of thalassemia, spherocytosis, history of GI bleeding), or for whom anaemia would be medically problematic;
  • Documented or presumed coronary artery disease or cerebrovascular disease if, in the judgment of the investigator, an acute decrease in haemoglobin by up to 4g/dL (as may be seen with ribavirin therapy) would not be well-tolerated.

SECONDARY PARTICIPANTS INCLUSION AND EXCLUSION CRITERIA

The INCLUSION criteria for secondary participants are as follows:

  • Is nominated by a primary participant as a current injecting partner (i.e., has engaged in IDU with a primary participant in the previous six months)
  • Willing and able to provide written informed consent.

There are no exclusion criteria for secondary participants who are not receiving HCV therapy in this protocol:

EXCLUSION criteria for treated secondary participants (i.e., those in Group C who are HCV positive) are as follows:

  • History of, or current, decompensated liver disease
  • Women who are pregnant or breastfeeding, or men with female partners who are pregnant at screening or baseline, or who were pregnant in the six months prior to screening
  • Testing positive for HIV
  • Testing positive for HBsAg
  • HCC
  • Evidence of any condition, therapy, laboratory abnormality or other circumstance (current or prior) that may confound the study's results, or interfere with participation for the full duration of the study, such that it is not in the best interest of the participant
  • Use of concomitant medications.

Additional EXCLUSION criteria for secondary participants with HCV genotypes 2-6:

  • Increased baseline risk for anaemia (e.g. a history of thalassemia, spherocytosis, history of GI bleeding) or for whom anaemia would be medically problematic
  • Documented or presumed coronary artery disease or cerebrovascular disease if, in the judgment of the investigator, an acute decrease in haemoglobin by up to 4g/dL (as may be seen with ribavirin therapy) would not be well-tolerated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02363517


Contacts
Layout table for location contacts
Contact: Dr Joseph Doyle +61392822111 j.doyle@burnet.edu.au
Contact: Dr Brendan Quinn +61392822111 brendanq@burnet.edu.au

Locations
Layout table for location information
Australia, Victoria
Burnet Institute Recruiting
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
St Vincent's Hospital Melbourne
Investigators
Layout table for investigator information
Principal Investigator: Prof Margaret Hellard Burnet Institute
Principal Investigator: Prof Alexander Thompson St Vincent's Hospital Melbourne
Layout table for additonal information
Responsible Party: Macfarlane Burnet Institute for Medical Research and Public Health Ltd
ClinicalTrials.gov Identifier: NCT02363517    
Other Study ID Numbers: MacfarlaneBIMRPH
First Posted: February 16, 2015    Key Record Dates
Last Update Posted: April 10, 2018
Last Verified: April 2018
Keywords provided by Macfarlane Burnet Institute for Medical Research and Public Health Ltd:
Hepatitis
Viral
Non-A
Non-B
Parenterally-Transmitted
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis C
Hepatitis
Substance-Related Disorders
Substance Abuse, Intravenous
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
RNA Virus Infections
Flaviviridae Infections
Chemically-Induced Disorders
Mental Disorders
Sofosbuvir
Antiviral Agents
Anti-Infective Agents